$COEP NEWS: Coeptis Inc. (COEP) Expands Cancer Imm
Post# of 105125
(Total Views: 109)
Posted On: 03/18/2025 3:23:10 PM
$COEP NEWS: Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License
GetNews - TGAM - GetNews - Fri Mar 14, 4:16AM CDT
COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities
Coeptis Inc. (Nasdaq: COEP) has taken a bold step forward in the fight against cancer by securing exclusive worldwide development and commercialization rights to the groundbreaking GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform. This acquisition positions Coeptis as a leader in innovative oncology solutions, making it an attractive opportunity for traders and investors looking for high-growth potential in the biotech sector.
What Makes GEAR-NK a Game-Changer?
GEAR-NK (Gene-Edited Antibody Resistant Natural Killer Cells) represents a first-in-class approach to optimizing cancer immunotherapy. Unlike traditional NK cells that may be neutralized when used alongside monoclonal antibodies (mAbs), GEAR-NK cells are engineered to resist antibody-based depletion. This advancement allows for a synergistic effect, enhancing the potency and efficacy of combination cancer treatments.
By integrating GEAR technology into hematopoietic stem cells (HSCs), Coeptis is also exploring improved outcomes for bone marrow transplants, offering potential breakthroughs in treating hematologic malignancies. This pioneering approach has the potential to significantly enhance patient response rates and expand the market for Coeptis’ next-generation therapies.
Expert Endorsement and Market Potential
Dr. Evren Alici, a renowned expert from Karolinska Institutet and a member of COEP’s Scientific Advisory Board, emphasized that GEAR-based immunotherapy offers a differentiated and highly promising strategy in cancer treatment. Specifically, the ability to co-administer NK cells with CD38-targeting mAbs for multiple myeloma treatment while minimizing “on-target/off-tumor” effects could redefine how antibody-based therapies are delivered.
Coeptis CEO Dave Mehalick stated, “The market potential of GEAR is extensive and is driven by therapeutic need. GEAR, integrated into our allogeneic cellular immunotherapy platform, has the potential to provide a beneficial, cost-effective therapeutic option available to all patients in need.”
Strategic Expansion with GEAR Therapeutics, Inc.
To accelerate the commercialization of the GEAR platform, Coeptis has established GEAR Therapeutics, Inc., a majority-owned subsidiary dedicated to advancing GEAR-based cell therapies into human clinical trials. This move underscores Coeptis’ commitment to maximizing the value of its newly acquired technology and positioning itself as a dominant player in next-generation cancer immunotherapies.
Potential Investment Opportunity in COEP
For investors, COEP presents a compelling growth opportunity in the rapidly evolving immunotherapy market. With exclusive rights to a novel cell therapy platform, strategic partnerships with globally recognized institutions like Karolinska Institutet, and a leadership team focused on clinical execution, Coeptis is well-positioned for long-term success.
As Coeptis progresses towards clinical proof-of-concept studies for GEAR-NK, traders and investors should keep a close watch on COEP. The potential for breakthrough therapies, combined with the expanding market for immune cell therapies, makes this stock an exciting prospect in the biotechnology sector.
Summary
Coeptis’ exclusive GEAR license signals a significant advancement in immunotherapy and a prime opportunity for investors looking to capitalize on biotech innovation. As the company continues to expand its pipeline and advance towards clinical trials, COEP’s stock could become a high-value asset in the healthcare sector. Stay tuned for further developments as Coeptis transforms cancer treatment with its pioneering technologies.
About VyGen-Bio, Inc.
VyGen-Bio, a majority-owned subsidiary of Vycellix, Inc., operates in both Florida and Stockholm, Sweden. Its technology platforms were developed by leading researchers at Karolinska Institutet and are part of NextGenNK, an internationally recognized center for NK cell-based cancer immunotherapies.
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"
, is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Other notable biotech stocks to keep on top of radar include (NASDAQ: VRTX) Vertex Pharmaceuticals Incorporated), (NASDAQ: REGN) Regeneron Pharmaceuticals, Inc., (NASDAQ: ALNY) Alnylam Pharmaceuticals, Inc., (NASDAQ: RPRX) Royalty Pharma plc, (NASDAQ: SMMT) Summit Therapeutics Inc.
For more details, visit www.VyGen-Bio.com.
Source: https://finance.yahoo.com/news/coeptis-therap...00980.html
GetNews - TGAM - GetNews - Fri Mar 14, 4:16AM CDT
COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities
Coeptis Inc. (Nasdaq: COEP) has taken a bold step forward in the fight against cancer by securing exclusive worldwide development and commercialization rights to the groundbreaking GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform. This acquisition positions Coeptis as a leader in innovative oncology solutions, making it an attractive opportunity for traders and investors looking for high-growth potential in the biotech sector.
What Makes GEAR-NK a Game-Changer?
GEAR-NK (Gene-Edited Antibody Resistant Natural Killer Cells) represents a first-in-class approach to optimizing cancer immunotherapy. Unlike traditional NK cells that may be neutralized when used alongside monoclonal antibodies (mAbs), GEAR-NK cells are engineered to resist antibody-based depletion. This advancement allows for a synergistic effect, enhancing the potency and efficacy of combination cancer treatments.
By integrating GEAR technology into hematopoietic stem cells (HSCs), Coeptis is also exploring improved outcomes for bone marrow transplants, offering potential breakthroughs in treating hematologic malignancies. This pioneering approach has the potential to significantly enhance patient response rates and expand the market for Coeptis’ next-generation therapies.
Expert Endorsement and Market Potential
Dr. Evren Alici, a renowned expert from Karolinska Institutet and a member of COEP’s Scientific Advisory Board, emphasized that GEAR-based immunotherapy offers a differentiated and highly promising strategy in cancer treatment. Specifically, the ability to co-administer NK cells with CD38-targeting mAbs for multiple myeloma treatment while minimizing “on-target/off-tumor” effects could redefine how antibody-based therapies are delivered.
Coeptis CEO Dave Mehalick stated, “The market potential of GEAR is extensive and is driven by therapeutic need. GEAR, integrated into our allogeneic cellular immunotherapy platform, has the potential to provide a beneficial, cost-effective therapeutic option available to all patients in need.”
Strategic Expansion with GEAR Therapeutics, Inc.
To accelerate the commercialization of the GEAR platform, Coeptis has established GEAR Therapeutics, Inc., a majority-owned subsidiary dedicated to advancing GEAR-based cell therapies into human clinical trials. This move underscores Coeptis’ commitment to maximizing the value of its newly acquired technology and positioning itself as a dominant player in next-generation cancer immunotherapies.
Potential Investment Opportunity in COEP
For investors, COEP presents a compelling growth opportunity in the rapidly evolving immunotherapy market. With exclusive rights to a novel cell therapy platform, strategic partnerships with globally recognized institutions like Karolinska Institutet, and a leadership team focused on clinical execution, Coeptis is well-positioned for long-term success.
As Coeptis progresses towards clinical proof-of-concept studies for GEAR-NK, traders and investors should keep a close watch on COEP. The potential for breakthrough therapies, combined with the expanding market for immune cell therapies, makes this stock an exciting prospect in the biotechnology sector.
Summary
Coeptis’ exclusive GEAR license signals a significant advancement in immunotherapy and a prime opportunity for investors looking to capitalize on biotech innovation. As the company continues to expand its pipeline and advance towards clinical trials, COEP’s stock could become a high-value asset in the healthcare sector. Stay tuned for further developments as Coeptis transforms cancer treatment with its pioneering technologies.
About VyGen-Bio, Inc.
VyGen-Bio, a majority-owned subsidiary of Vycellix, Inc., operates in both Florida and Stockholm, Sweden. Its technology platforms were developed by leading researchers at Karolinska Institutet and are part of NextGenNK, an internationally recognized center for NK cell-based cancer immunotherapies.
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"
, is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts. The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Other notable biotech stocks to keep on top of radar include (NASDAQ: VRTX) Vertex Pharmaceuticals Incorporated), (NASDAQ: REGN) Regeneron Pharmaceuticals, Inc., (NASDAQ: ALNY) Alnylam Pharmaceuticals, Inc., (NASDAQ: RPRX) Royalty Pharma plc, (NASDAQ: SMMT) Summit Therapeutics Inc.
For more details, visit www.VyGen-Bio.com.
Source: https://finance.yahoo.com/news/coeptis-therap...00980.html
(0)
(0)
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.
Scroll down for more posts ▼